Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29710362 | 0.80 | HTT (0.49) | TSHRAPOBEC3AHTTAPOBEC3GPARP1 | |
| SCHEMBL19358016 | 0.80 | HTT (0.49) | TSHRAPOBEC3AHTTAPOBEC3GPARP1 | |
| SCHEMBL18471225 | 0.80 | SMN1; SMN2 (0.49) | TSHRAPOBEC3AHTTAPOBEC3GPARP1 | |
| SCHEMBL10831613 | 0.80 | PARP1 (0.46) | TSHRAPOBEC3AHTTAPOBEC3GPARP1 | |
| SCHEMBL1004660 | 0.78 | PARP1 (0.50) | TSHRAPOBEC3AHTTAPOBEC3GPARP1 | |
| SCHEMBL12983073 | 0.78 | CA5A (0.48) | SMN1; SMN2MAPTTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL1397262 | 0.78 | POLB (0.50) | TSHRAPOBEC3AHTTAPOBEC3GPARP1 | |
| SCHEMBL850504 | 0.78 | TPMT (0.54) | TSHRSMN1; SMN2MAPTHSD17B10TDP1 | |
| SCHEMBL3220166 | 0.78 | CA1 (0.48) | TSHRPARP1CYP3A4SMN1; SMN2MAPT | |
| SCHEMBL1002938 | 0.76 | CYP3A4 (0.48) | TSHRAPOBEC3AHTTAPOBEC3GPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026032-B | Method for producing optically active 4-carbamoyl-2, 6-dimethylphenylalanine derivative | 株式会社钟化 | 2020-09-29 | — | — | CN | disclosed |
| EP-3068768-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3068768-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3112352-B1 | OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-21 | — | — | EP | disclosed |
| US-20180325870-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2018-11-15 | — | — | US | disclosed |
| US-9700542-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-11 | — | — | US | disclosed |
| US-9700542-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-11 | — | — | US | disclosed |
| US-9700542-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-11 | — | — | US | disclosed |
| EP-3112352-A1 | OPIOID RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2017-01-04 | — | — | EP | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20080096888-A1 | pain relievers; gastrointestinal disorders; inflammatory bowel disease, diarrhea, motility disorders; aminoacetamide derivatives substituted with an imidazole; 5-(([2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino)-methyl)-2-methoxy-benzoic acid | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| EP-1863764-A1 | PROCESS FOR THE PREPARATION OF OPIOID MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-12 | — | — | EP | disclosed |
| EP-1858850-A2 | PROCESS FOR THE PREPARATION OF OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-28 | — | — | EP | disclosed |
| EP-1725537-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006099060-A2 | PROCESS FOR THE PREPARATION OF OPIOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006098982-A1 | PROCESS FOR THE PREPARATION OF OPIOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211861-A1 | Process for the preparation of opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-21 | — | — | US | disclosed |
| US-20060211863-A1 | Process for the preparation of opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-21 | — | — | US | disclosed |
| WO-2005090315-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N. V. (BE) | 2005-09-29 | — | — | WO | disclosed |
| US-20050203143-A1 | use as pain relievers, gastrointestinal disorders such as inflammatory bowel disease; compounds are aminoacetamide derivatives substituted with an imidazole; 5-(([2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino)-methyl)-2-methoxy-benzoic acid for example | JANSSEN PHARMACEUTICA, N. V. (BE) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203143-A1 | use as pain relievers, gastrointestinal disorders such as inflammatory bowel disease; compounds are aminoacetamide derivatives substituted with an imidazole; 5-(([2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino)-methyl)-2-methoxy-benzoic acid for example | OPRK1, OPRM1, OPRL1 | TSHR 2171/4885APOBEC3A 4607/4885HTT 3825/4885 |
| US-20060211861-A1 | Process for the preparation of opioid modulators | OPRM1, OPRK1, OPRL1 | TSHR 1255/4885APOBEC3A 4053/4885HTT 2747/4885 |
| US-20080096888-A1 | pain relievers; gastrointestinal disorders; inflammatory bowel disease, diarrhea, motility disorders; aminoacetamide derivatives substituted with an imidazole; 5-(([2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino)-methyl)-2-methoxy-benzoic acid | OPRK1, OPRM1, OPRL1 | TSHR 1793/4885APOBEC3A 4489/4885HTT 3902/4885 |
| US-20180325870-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | TSHR 410/4885APOBEC3A 4783/4885HTT 3569/4885 |
| US-20060211863-A1 | Process for the preparation of opioid modulators | OPRM1, OPRK1, OPRL1 | TSHR 1255/4885APOBEC3A 4053/4885HTT 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.